Bluebird bio : SGD Corporate Presentation

bluebird bio

Company Presentation

September 2021

NASDAQ: BLUE

CONFIDENTIAL 1

Forward-looking Statements

These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward-looking statements. For example, all statements we make regarding our research and development programs, the timing or likelihood of regulatory filings and approvals, and the timing and likelihood of entering into contracts with payors for value-based payments over time or reimbursement approvals, and our commercialization plans for approved products are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These statements are also subject to a number of material risks and uncertainties that are described in our most recent quarterly report on Form 10-Q, as well as our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

2

Bringing transformative therapies to people with severe genetic diseases is our mission

Sickle-Cell Disease*	Thalassemia*	Cerebral
Adrenoleukodystrophy*
Zero severe	89% of patients across all	Zero major functional
vaso-occlusive events	ages and genotypes become	disabilities in the 27 boys who
following treatment vs.	transfusion independent in	completed our ALD-102 study
a median of 3 per year	our Phase III studies	with up to nearly 7 years of
in our HGB-206 study		follow-up

*Real patients pictured, but they have not used our products

3

The next chapter of bluebird bio begins now

Products that Matter

Focused on delivering our Core 3 first-in- class transformative gene therapies to patients and their families in need

Optimization + Innovation

Strategy in place to optimize existing products and realize next-generation pipeline

Leadership Team

Experienced team composed of tenured bluebird leaders and recent additions

Post-separation,

bluebird is

poised to

unlock value

for patients and

shareholders

Commercial Execution

Laser-focused on launching Core 3

products in the U.S.

Funding + Financial

Increased fiscal discipline; well-funded to execute through significant value- creating milestones

4

Leadership Team

Experienced management team in place

bluebird leaders

Recent additions

Andrew Obenshain	Richard Colvin	Jason Cole	Gina Consylman
Chief Executive Officer	Chief Medical Officer	Chief Business Officer	Chief Financial Officer

Anne-Virginie Eggimann	Melissa Bonner	Kasra Kasraian	Scott Shoemaker	Tom Klima
Chief Regulatory Officer	Head of SGD Research	SVP, CMC Strategy &	SVP, SGD Quality	Chief Commercial Officer
		Operations		5